IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
IGC Pharma, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.24−0.00 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $24.28M
- P/E (TTM)
- –
- Dividend yield
- –
IGC Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Market Cap | $25.02M | $197.05M |
| Enterprise Value | $24.81M | $106.56M |
| PS Ratio | 22.28 | 3.93 |
| PB Ratio | 4.08 | 2.14 |
| P/TBV Ratio | 40.03 | 2.46 |
Enterprise value
| Measure | IGC Pharma | Industry median |
|---|---|---|
| EV / Sales | 22.10 | 2.69 |
Income (trailing twelve months)
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Revenue | $1.12M | $57.94M |
| Gross Profit | $246.00K | $90.47M |
| Operating Income | -$11.08M | -$21.44M |
| Pretax Income | -$7.89M | -$14.45M |
| Net Income | -$7.89M | -$22.46M |
| EBITDA | -$11.08M | -$16.91M |
| EPS (Diluted) | -$0.08 | -$0.83 |
Margins
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Gross Margin | 21.9% | 52.3% |
| Operating Margin | -986.8% | -44.5% |
| Pretax Margin | -702.1% | -13.0% |
| Profit Margin | -702.1% | -39.2% |
| EBITDA Margin | -986.8% | -31.3% |
Returns
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -129.2% | -53.1% |
| Return on Assets (ROA) | -90.4% | -41.0% |
| Return on Invested Capital (ROIC) | -149.8% | -32.0% |
| Return on Capital Employed (ROCE) | -176.4% | -37.8% |
Growth
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -15.4% | 6.01% |
Balance sheet
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $354.00K | $62.42M |
| Total Debt | $149.00K | $120.13M |
| Net Cash (Debt) | $205.00K | $15.68M |
| Net Cash Per Share | $0.00 | $0.65 |
| Equity (Book Value) | $6.13M | $48.79M |
| Book Value Per Share | $0.06 | $1.36 |
| Tangible Book Value | $625.00K | $23.06M |
| Working Capital | -$1.95M | $75.77M |
Financial position
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Current Ratio | 0.39 | 3.30 |
| Quick Ratio | 0.13 | 2.39 |
| Debt / Equity | 0.02 | 0.51 |
Efficiency
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Inventory Turnover | 0.88 | 2.67 |
| Revenue Per Employee | $16.76K | $398.96K |
| Profits Per Employee | -$117.69K | -$732.08K |
| Employee Count | 67 | 73 |
Dividends and yields
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Earnings Yield | -31.5% | -21.2% |
Shares
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 103,384,000 | 59,128,900 |
| Shares Change (YoY) | 20.8% | 11.1% |
| Shares Change (QoQ) | 3.67% | 0.54% |
| Float | 89,703,500 | 48,744,500 |
| Shares Held by Insiders | 13.2% | 11.8% |
| Shares Held by Institutions | 5.08% | 59.4% |
Taxes
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | IGC Pharma | Industry median |
|---|---|---|
| Altman Z-Score | -18.72 | 0.10 |
Calculated by StockData from IGC Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.